Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mind Medicine Mindmed Inc (NQ: MNMD ) 5.890 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mind Medicine Mindmed Inc < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex February 18, 2024 IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... Via Talk Markets Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More February 15, 2024 Via Benzinga Why Is ARB IOT (ARBB) Stock Up 230% Today? February 13, 2024 ARB IOT stock is taking off on Tuesday after providing investors with a shareholder update and heavy trading of ARBB shares this morning. Via InvestorPlace Why Is MindMed (MNMD) Stock Up 8% Today? February 12, 2024 MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers. Via InvestorPlace Exposures Product Safety MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference February 07, 2024 From MindMed Via Business Wire Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' — This Psychedelic Bio-Tech Company Hopes To Help Build That Future February 05, 2024 Via Benzinga FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000 January 31, 2024 FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address... Via Benzinga Exposures Product Safety 5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week January 30, 2024 The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Via Talk Markets Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... Via Benzinga How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition January 24, 2024 EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety 5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week January 13, 2024 The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. Via Talk Markets Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued January 11, 2024 Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The... Via Benzinga Why Is Clearmind (CMND) Stock Up 40% Today? January 10, 2024 The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing. Via InvestorPlace MindMed Announces Business Update and Anticipated Milestones for 2024 January 08, 2024 From Mind Medicine (MindMed) Inc. Via Business Wire Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More January 07, 2024 Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Via Benzinga Psychedelic Stock Gainers And Losers From January 1, 2024 January 01, 2024 Via Benzinga Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... Via Benzinga Psychedelic Drug Stocks Index Up In December; Down YTD December 27, 2023 The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. Via Talk Markets Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More December 18, 2023 Biden To Decide On Psychedelic Therapy Bill Via Benzinga Psychedelic Drug Stocks Index Declined 1.6% This Week December 17, 2023 Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. Via Talk Markets Topics ETFs Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed December 14, 2023 Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no... Via Benzinga MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder December 14, 2023 From Mind Medicine Via Business Wire Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More December 11, 2023 John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy Via Benzinga 5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week December 10, 2023 The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. Via Talk Markets Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More December 05, 2023 Defense Dept. Funds Ketamine Study For PTSD Treatment Via Benzinga November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex December 02, 2023 The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November. Via Talk Markets Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Via Benzinga Topics Cannabis Exposures Cannabis GH Research, Compass Pathways Among Top Psychedelic Movers Of Today November 23, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.